Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.

Expert review of anticancer therapy - 1 Oct 2021

Henriques-Abreu Miguel, Serrano César

Abstract excerpt

INTRODUCTION: Avapritinib (formerly known as BLU-285) is an orally available type I tyrosine kinase inhibitor that, in 2020, obtained regulatory approval for the treatment of patients with gastrointestinal stromal tumors (GISTs) harboring a primary mutation in PDGFRA exon 18, including the PDGFRA D842V mutation. AREAS COVERED: Herein, we comprehensively review the available efficacy and safety data on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precision Medicine

Share to Proto-Oncogene Proteins c-kit

Share to Pyrazoles

Share to Pyrroles

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Triazines

Source

Identifiers

PMID: 34404327
DOI: 10.1080/14737140.2021.1963235

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.PMID 34404327Read ↗

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.Semantic proximity Read ↗

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.Semantic proximity Read ↗

Avapritinib for metastatic or unresectable gastrointestinal stromal tumors.Semantic proximity Read ↗

The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation.Semantic proximity Read ↗

Avapritinib: First Approval.Semantic proximity Read ↗

Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.Semantic proximity Read ↗

Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.Semantic proximity Read ↗

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.Semantic proximity Read ↗

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world dataSemantic proximity Read ↗

Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.Semantic proximity Read ↗

The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)Semantic proximity Read ↗

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.